{
    "id": 12644,
    "fullName": "ARID1A dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ARID1A dec exp indicates decreased expression of the Arid1a protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8289,
        "geneSymbol": "ARID1A",
        "terms": [
            "ARID1A",
            "B120",
            "BAF250",
            "BAF250a",
            "BM029",
            "C1orf4",
            "CSS2",
            "ELD",
            "hELD",
            "hOSA1",
            "MRD14",
            "OSA1",
            "P270",
            "SMARCF1"
        ]
    },
    "variant": "dec exp",
    "createDate": "09/30/2015",
    "updateDate": "09/30/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited growth of ovarian cancer cells with knockdown of ARID1A expression in culture (PMID: 25686104).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3263,
                    "pubMedId": 25686104,
                    "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25686104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4293,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2545,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talazoparib (BMN-673) selectively inhibited growth and induced apoptosis in breast cancer cells with knock-down of ARID1A in culture, and inhibited tumor growth in ARID1A-deficient breast cancer cell line xenograft models (PMID: 26069190).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human mammary epithelial cells with knockdown of ARID1A demonstrated resistance to Talazoparib (BMN673) when compared to parental cells in culture (PMID: 29669295).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11296,
                    "pubMedId": 29669295,
                    "title": "A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29669295"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16566,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with APR-246, demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14629,
                    "pubMedId": 30686770,
                    "title": "Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30686770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Molibresib (GSK525762) in ovarian clear cell carcinoma cell lines in culture (PMID: 29760405).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13211,
                    "pubMedId": 29760405,
                    "title": "ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29760405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4292,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Veliparib (ABT-888) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Talazoparib (BMN-673) in ovarian cancer cells in culture (PMID: 26069190).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3200,
                    "pubMedId": 26069190,
                    "title": "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26069190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).",
            "molecularProfile": {
                "id": 12806,
                "profileName": "ARID1A dec exp"
            },
            "therapy": {
                "id": 4989,
                "therapyName": "Buthionine sulfoximine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14629,
                    "pubMedId": 30686770,
                    "title": "Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30686770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARID1A-deficient ovarian cancer cells with decreased expression of SLC7A11 were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival in culture (PMID: 30686770).",
            "molecularProfile": {
                "id": 31682,
                "profileName": "ARID1A dec exp SLC7A11 dec exp"
            },
            "therapy": {
                "id": 4989,
                "therapyName": "Buthionine sulfoximine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14629,
                    "pubMedId": 30686770,
                    "title": "Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30686770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARID1A-deficient ovarian cancer cells with decreased expression of SLC7A11 were sensitive to treatment with APR-246, demonstrating decreased cell survival in culture (PMID: 30686770).",
            "molecularProfile": {
                "id": 31682,
                "profileName": "ARID1A dec exp SLC7A11 dec exp"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14629,
                    "pubMedId": 30686770,
                    "title": "Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30686770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Platinol (cisplatin) resulted in enhanced reduction in cell viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9442,
                "therapyName": "Cisplatin + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20759,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 in combination with Adrucil (fluorouracil) resulted in enhanced reduction in cell viability and induced apoptosis in in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 9441,
                "therapyName": "Fluorouracil + GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20757,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK690693 treatment inhibited phosphorylation of Akt and S6, reduced viability and induced apoptosis in ARID1A knockdown gastric cancer cell lines expressing AKT1 in culture (PMID: 28860825).",
            "molecularProfile": {
                "id": 35327,
                "profileName": "AKT1 pos ARID1A dec exp"
            },
            "therapy": {
                "id": 3073,
                "therapyName": "GSK690693",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18025,
                    "pubMedId": 28860825,
                    "title": "AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28860825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 12804,
            "profileName": "ARID1A dec exp PIK3IP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12805,
            "profileName": "ARID1A dec exp PIK3CA act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 12806,
            "profileName": "ARID1A dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31682,
            "profileName": "ARID1A dec exp SLC7A11 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35327,
            "profileName": "AKT1 pos ARID1A dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}